Symptomatic CTRCD is defined by the presence of HF symptoms; the diagnosis of asymptomatic CTRCD is based on the left ventricular ejection fraction (LVEF) reduction and/or relative decline in global longitudinal strain (GLS) and/or a new rise in cardiac biomarkers (cTnI/cTnT gammaGT; 99th percentile, BNP ≥ 35 pg/mL, NT-proBNP ≥ 125 pg/mL, or a new significant rise from baseline beyond the biological and analytical variations of the assay used) [39]. Here, TNNI3 is linked to hydrops fetalis.